Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
NCT02383433Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jun 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in pancreatic adenocarcinoma (PDAC), sponsored by Case Comprehensive Cancer Center. Started Jun 2016; status: terminated.
02
Drugs
regorafenib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02383433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383433.